Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy

详细信息    查看全文

• 作者：Paulo H.N. Harada ; MD ; MPH ; PhD^a ; Nancy R. Cook ; ScD^a ; David E. Cohen ; MD ; PhD^b ; Nina P. Paynter ; PhD^a ; Lynda Rose ; MS^a ; Paul M Ridker ; MD ; MPH^a ; ^{pridker@partners.org" class="auth_mail" title="E-mail the corresponding author}
• 刊名：The American Journal of Cardiology
• 出版年：2016
• 出版时间：1 July 2016
• 年：2016
• 卷：118
• 期：1
• 页码：49-55
• 全文大小：645 K

文摘

The relation between hepatic serum markers within the normal range and cardiovascular risk is uncertain. We sought to address this issue within a prospective randomized trial of statin therapy. Men and women (n = 17,515) free of cardiovascular disease participating in a randomized placebo controlled trial of rosuvastatin 20 mg/day had baseline levels of alanine aminotransferase (ALT) below <40 IU/l and were followed prospectively for the first-ever cardiovascular events. Cox proportional hazards models were used to calculate the relative risks of these events according to increasing tertiles and each SD increase in baseline ALT levels. ALT levels at study entry, all within the normal range, were inversely associated with age, smoking status, and inflammation and were positively associated with male gender, alcohol use, and triglycerides. Incident cardiovascular event rates were highest in those in the lowest tertile of baseline ALT; specifically, incidence rates were 1.43, 0.98, and 0.85 per 100 person-years of exposure for those in the lowest, middle, and highest tertile of baseline ALT within the normal range, respectively (p <0.001). These inverse effects remained statistically significant after multivariate adjustment for a wide range of vascular risk factors risk markers such that each higher SD unit of ALT was associated with an 18% lower event rate (relative risk 0.82, 95% confidence interval 0.72 to 0.93, p = 0.002). The efficacy of statin therapy was not modified by baseline ALT level. In conclusion, increasing ALT levels within the normal range are inversely associated with future cardiovascular risk but had limited clinical utility and also did not modify the efficacy of statin therapy.